Additional studies are required to investigate possible interactions between the peripheral GLP-1 system and oxytocin-mediated food intake reductions, particularly given there several long-acting GLP-1 analogs are FDA-approved for obesity and diabetes treatment. This evidence concerns the gene OXT and obesity due to melanocortin 4 receptor deficiency.